Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709748 | 0.84 | PRKDC (0.50) | ERN1PRKDCLMNATRIM24TRIM33 | |
| SCHEMBL3562577 | 0.83 | ERN1 (0.44) | ERN1ESR1ESR2PIM1TRIM24 | |
| SCHEMBL2336761 | 0.82 | ERN1 (0.50) | ERN1PRKDCLMNAPIM1TRIM24 | |
| SCHEMBL680308 | 0.80 | ERN1 (0.48) | ERN1PRKDCLMNAPIM1TRIM24 | |
| SCHEMBL415162 | 0.78 | ERN1 (0.50) | ERN1ESR1ESR2TRIM24TRIM33 | |
| SCHEMBL31114205 | 0.78 | ERN1 (0.50) | ERN1ESR1ESR2TRIM24TRIM33 | |
| SCHEMBL12813947 | 0.78 | ERN1 (0.50) | ERN1ESR1ESR2TRIM24TRIM33 | |
| SCHEMBL23832884 | 0.77 | PRKDC (0.44) | ERN1PRKDCLMNA | |
| SCHEMBL19837992 | 0.77 | ERN1 (0.50) | ERN1TRIM24TRIM33 | |
| SCHEMBL31117267 | 0.77 | ERN1 (0.50) | ERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| WO-2023078413-A1 | FGFR2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 微境生物医药科技(上海)有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20220226298-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3976576-A1 | GPR40 AGONISTS | Kallyope, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | LES LABORATOIRES SERVIER (FR) | 2021-07-13 | — | — | US | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200261464-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2020-08-20 | — | — | US | disclosed |
| US-10688101-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2020-06-23 | — | — | US | disclosed |
| US-20190192528-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-06-27 | — | — | US | disclosed |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011094450-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| CN-102014927-A | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC | 2011-04-13 | — | — | CN | disclosed |
| EP-2187893-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | PDCD11, RRM2B, RRS1 | ERN1 2317/4885PRKDC 3273/4885LMNA 3288/4885 |
| US-20220226298-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | ERN1 4044/4885PRKDC 4869/4885LMNA 4674/4885 |
| US-20200261464-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRS1, RRM2B | ERN1 2312/4885PRKDC 3698/4885LMNA 3332/4885 |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | ERN1 2505/4885PRKDC 3610/4885LMNA 3213/4885 |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | ERN1 1887/4885PRKDC 3894/4885LMNA 3610/4885 |
| US-10688101-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | PDCD11, RRM2B, RRM2 | ERN1 2505/4885PRKDC 3610/4885LMNA 3213/4885 |
| US-20190192528-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | ERN1 2505/4885PRKDC 3610/4885LMNA 3213/4885 |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | ERN1 3508/4885PRKDC 4793/4885LMNA 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.